Gene therapy for hemophilia typically involves the use of viral vectors, such as adeno-associated viruses (AAV), to deliver the correct gene to the patient's liver cells. Once inside the cells, the gene begins to produce the missing clotting factor. This approach has shown promise in early clinical trials, with patients experiencing significant reductions in bleeding episodes.
